comparemela.com

Latest Breaking News On - லாப்கோர்ப் மருந்து - Page 1 : comparemela.com

OmniSeq Receives New York State Approval for OmniSeq INSIGHT Genomic and Immune Profiling Test

Seeing Your Doctor During the Pandemic

Seeing Your Doctor During the Pandemic News provided by Share this article Share this article MISSION, Kan., March 8, 2021 /PRNewswire/  (Family Features) If you ve been putting off a visit to your doctor during COVID-19, you re not alone. Most adults (57%) agree the pandemic has changed how they feel about going to a health care provider s office, according to a survey of 1,000 adults in October 2020 from a national alliance of health care experts working to stop medical distancing, which was commissioned and sponsored by AbbVie. Photos courtesy of Getty Images The survey showed that in adults with chronic diseases, cancellations of their visits to the doctor amounted to 61%. Of those that had canceled appointments, 18% did not reschedule them. Some of the reasons included concerns about contracting COVID-19, not wanting to go into the hospital if not necessary and believing they can hold off on care until the end of the pandemic.

PathAI and Labcorp Broaden Strategic Collaboration to Accelerate Use of AI-Powered Pathology

PathAI and Labcorp Broaden Strategic Collaboration to Accelerate Use of AI-Powered Pathology Share Article BOSTON and BURLINGTON, N.C. (PRWEB) March 08, 2021 PathAI, a global provider of artificial intelligence-powered (AI-powered) technology for use in pathology research, and Labcorp (NYSE: LH), a leading global life sciences company, today announced the broadening of their strategic partnership in the field of AI-powered pathology. The collaboration builds on Labcorp’s past investment in PathAI and the companies’ collaboration on a series of projects, including the deployment of PathAI algorithms in clinical trials managed by Labcorp Drug Development. A key focus of the expanded collaboration will be to enable, in prospective clinical trials of cancer and other diseases, the seamless deployment of PathAI’s algorithms in the broad portfolio of programs managed by Labcorp Drug Development. These PathAI algo

TrakCel Fuels Growth and Increased Market Access Through Strategic Investment Round

TrakCel Fuels Growth and Increased Market Access Through Strategic Investment Round Thursday, March 4, 2021 10:39AM IST (5:09AM GMT)   Cardiff, Wales, United Kingdom:   TrakCel, a leading supplier of cellular orchestration solutions supporting the cell and gene therapy industry, today announces that it has closed its latest funding round led by AmerisourceBergen and Labcorp (NYSE: LH). These strategic investments enable further transformation of TrakCel’s cellular therapy orchestration solution, growth of its existing partner ecosystem, and continued global expansion.   The company will use both the investment and the combined expertise gained from collaborations with the investors to further augment its offering to both clinical and commercial-stage cell and gene therapy developers as part of its drive toward industry standardization and future innovation.

Presage Sets the Stage for Commercial Expansion with Closing of $13M Financing and Execution of New Phase 0 Trial Agreements with Merck and Maverick Therapeutics

Presage Sets the Stage for Commercial Expansion with Closing of $13M Financing and Execution of New Phase 0 Trial Agreements with Merck and Maverick Therapeutics - Funds to Support Expansion of CIVO® Technology Platform - New Collaborations to Utilize CIVO for Phase 0 Studies News provided by Share this article Share this article SEATTLE, March 2, 2021 /PRNewswire/ Presage Biosciences, Inc., a biotechnology company pioneering a new cancer drug development approach using its Comparative In Vivo Oncology (CIVO®) intratumoral microdosing platform, today announced the closing of a $13 million financing and commencement of new research collaborations with Merck, known as MSD outside of the United States and Canada, and Maverick Therapeutics.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.